Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.

被引：21
|
作者：
Lugtenburg, Pieternella J.
Brown, Peter de Nully
van der Holt, Bronno
D'Amore, Francesco
Koene, Harry R.
Berenschot, Henriette W.
Fijnheer, Rob
Loosveld, Olaf
Bohmer, Lara H.
Pruijt, Hans
Verhoef, Gregor
Hoogendoorn, Mels
de Kan, Romko
Van Imhoff, Gustaaf Willem
van Hooije, Christel
Lam, King H.
de Keizer, Bart
de Jong, Daphne
Hoekstra, Otto S.
Zijlstra, Josee M.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7504
引用
收藏
页数：2
相关论文
共 50 条
  • [1] RANDOMIZED PHASE III STUDY OF EARLY RITUXIMAB INTENSIFICATION IN COMBINATION WITH CHOP14 FOLLOWED BY RITUXIMAB OR NO MAINTENANCE IN DIFFUSE LARGE B-CELL LYMPHOMA: A HOVON-NORDIC LYMPHOMA GROUP STUDY
    Lugtenburg, P.
    Brown, P. de Nully
    van der Holt, B.
    d'Amore, F.
    Koene, H.
    Berenschot, H.
    Fijnheer, R.
    Loosveld, O.
    Bohmer, L.
    Pruijt, J.
    Verhoef, G.
    Hoogendoorn, M.
    de Kan, R.
    van Imhoff, G.
    van Hooije, C.
    Lam, K.
    de Keizer, B.
    de Jong, D.
    Hoekstra, O.
    Zijlstra, J.
    HAEMATOLOGICA, 2016, 101 : 173 - 173
  • [2] Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Results from a randomized HOVON-Nordic Lymphoma Group phase III study.
    Lugtenburg, Elly J.
    Brown, Peter
    van der Holt, Bronno
    D'Amore, Francesco
    Koene, Harry R.
    de Jongh, Eva
    Fijnheer, Rob
    Loosveld, Olaf
    Bohmer, Lara H.
    Pruijt, Hans
    Verhoef, Gregor
    Hoogendoorn, Mels
    Bilgin, Yavuz
    Nijland, Marcel
    Lam, King H.
    de Keizer, Bart
    de Jong, Daphne
    Zijlstra, Josee M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Rituximab Maintenance for Patients With Diffuse Large B-Cell Lymphoma in First Complete Remission: Results From a Randomized HOVON-Nordic Lymphoma Group Phase III Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 6 - 8
  • [4] Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)
    Lugtenburg, Pieternella Johanna
    Brown, Peter de Nully
    van der Holt, Bronno
    D'Amore, Francesco A.
    Koene, Harry R.
    de Jongh, Eva
    Fijnheer, Rob
    van Esser, Joost W.
    Boehmer, Lara H.
    Pruijt, Johannes F.
    Verhoef, Gregor E.
    Hoogendoorn, Mels
    Bilgin, Memis Y.
    Nijland, Marcel
    van der Burg-de Graauw, Nicole C.
    Oosterveld, Margreet
    Jie, Kon-Siong G.
    Larsen, Thomas Stauffer
    van der Poel, Marjolein W.
    Leijs, Maria B.
    Silbermann, Matthijs H.
    Kooy, Marinus van Marwijk
    Beeker, Aart
    Kersten, Marie J.
    Doorduijn, Jeanette K.
    Tick, Lidwine W.
    Brouwer, Rolf E.
    Lam, King H.
    Burggraaff, Coreline N.
    de Keizer, Bart
    Arens, Anne I.
    de Jong, Daphne
    Hoekstra, Otto S.
    Zijlstra-Baalbergen, Josee M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29) : 3377 - 3387
  • [5] Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Long-term results of the HOVON-84 randomized phase III study by the HOVON and the Nordic Lymphoma Group (clinical trial number: NTR1014)
    Lugtenburg, Pieternella Johanna
    Brown, Peter de Nully
    van der Hol, Bronno
    de Jongh, Eva
    Zijlstra, Josee M.
    EUROPEAN JOURNAL OF CANCER, 2025, 214
  • [6] Phase II study of 2-weekly CHOP plus Rituximab followed by yttrium 90 ibritumomab tiuxetan (Zevalin) in patients with previously untreated diffuse large B cell lymphoma (DLBCL)
    Venugopal, Parameswaran
    Gregory, Stephanie A.
    Obrien, Teresa
    Drasga, Ray
    Bayer, Robert
    BLOOD, 2007, 110 (11) : 198B - 199B
  • [7] Laboratory changes associated with rituximab treatment: A prospective study in diffuse large B-cell lymphoma (DLCL) patients randomized between CHOP and CHOP plus rituximab. A GELA study.
    Coiffier, B
    Bienvenu, J
    Chvetzoff, R
    Tilly, H
    Herbrecht, R
    Morel, P
    Lederlin, P
    Solal-Celigny, P
    Audhuy, B
    Christian, B
    Gabarre, J
    Casasnovas, O
    Marit, G
    Sebban, C
    Hooftman, L
    Salles, G
    BLOOD, 2000, 96 (11) : 138A - 138A
  • [8] Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).
    Micallef, IN
    Kahl, BS
    Gayko, U
    Cesano, A
    Ansell, SM
    Geyer, S
    Inwards, DJ
    Maurer, MJ
    Horning, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 577S - 577S
  • [9] A pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).
    Micallef, INM
    Kahl, BS
    Gayko, U
    Cesano, A
    Ansell, SM
    Colgan, JP
    Geyer, S
    Maurer, MJ
    Inwards, DJ
    White, WL
    Horning, SJ
    Habermann, TM
    BLOOD, 2003, 102 (11) : 643A - 644A
  • [10] Successful treatment of diffuse large B-cell lymphoma following Waldenstrom's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab
    Uchino, K
    Sameshima, H
    Miyamoto, T
    Iino, T
    Kato, K
    Henzan, H
    Aoki, K
    Nagafuji, K
    Gondo, H
    Harada, M
    INTERNAL MEDICINE, 2004, 43 (02) : 131 - 134
12345